A common TMPRSS2 variant has a protective effect against severe COVID-19
Open Access
- 1 May 2022
- journal article
- research article
- Published by Elsevier BV in Current Research in Translational Medicine
- Vol. 70 (2), 103333
- https://doi.org/10.1016/j.retram.2022.103333
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus EntryJournal of Virology, 2012
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune ResponseJournal of Virology, 2011
- Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, CondelAmerican Journal of Human Genetics, 2011
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus EntryJournal of Virology, 2011
- Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2Journal of Virology, 2010
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cellsBiochemical Journal, 2005
- UniProt: the Universal Protein knowledgebaseNucleic Acids Research, 2004
- CD6—ligand interactions: a paradigm for SRCR domain function?Immunology Today, 1997